

**KURZPROTOKOLL**  
**14V-MC-JAHN**

<b>Öffentlicher Titel</b>	Phase III Studie zu Baricitinib bei atopischer Dermatitis
<b>Wissenschaftl. Titel</b>	A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis
<b>Kurztitel</b>	14V-MC-JAHN
<b>Studienart</b>	multizentrisch, prospektiv, Therapiestudie, randomisiert, Pharma-Studie, doppelblind, mehrarmig
<b>Studienphase</b>	Phase III
<b>Erkrankung</b>	Haut: Ekzem (Dermatitis): Neurodermitis (Atopische Dermatitis)
<b>Einschlusskriterien</b>	<ul style="list-style-type: none"><li>- Have completed the final active treatment visit for an originating study eligible to enroll participants directly into study BREEZE-AD3 OR</li><li>- Meet criteria for NCT03334396 or NCT03334422</li></ul>
<b>Ausschlusskriterien</b>	<ul style="list-style-type: none"><li>- Had investigational product permanently discontinued at any time during a previous baricitinib study</li><li>- Had temporary investigational product interruption continue at the final study visit of a previous baricitinib study and, in the opinion of the investigator, this poses an unacceptable risk for the participant's participation in the study</li></ul>
<b>Alter</b>	18 Jahre und älter
<b>Prüfzentren</b>	<b>Klinik für Dermatologie, Venerologie und Allergologie</b> (Nachbeobachtung) Theodor-Stern-Kai 7 60590 Frankfurt am Main Dr. med. Andreas Pinter Tel: 069 6301-83115 Fax: 069 6301-83175 <a href="mailto:andreas.pinter@unimedizin-ffm.de">andreas.pinter@unimedizin-ffm.de</a>
<b>Sponsor</b>	Eli Lilly and Company
<b>Registrierung in anderen Studienregistern</b>	ClinicalTrials.gov NCT03334435 (primäres Register) EudraCT 2017-000873-35